U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H35N8O6P.C4H6O4
Molecular Weight 644.6144
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RABACFOSADINE SUCCINATE

SMILES

OC(=O)CCC(O)=O.CCOC(=O)[C@H](C)NP(=O)(COCCN1C=NC2=C1N=C(N)N=C2NC3CC3)N[C@@H](C)C(=O)OCC

InChI

InChIKey=XLBDQSJWTNREFA-IODNYQNNSA-N
InChI=1S/C21H35N8O6P.C4H6O4/c1-5-34-19(30)13(3)27-36(32,28-14(4)20(31)35-6-2)12-33-10-9-29-11-23-16-17(24-15-7-8-15)25-21(22)26-18(16)29;5-3(6)1-2-4(7)8/h11,13-15H,5-10,12H2,1-4H3,(H2,27,28,32)(H3,22,24,25,26);1-2H2,(H,5,6)(H,7,8)/t13-,14-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C21H35N8O6P
Molecular Weight 526.5264
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C4H6O4
Molecular Weight 118.088
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Rabacfosadine was approved in 2017 under the brand name Tanovea-CA1 for the treatment of canine lymphoma. In addition, this drug has demonstrated effectiveness against non-Hodgkin's lymphoma in dogs, as well as canine cutaneous T-cell lymphoma, and relapsed canine B-cell lymphoma. Rabacfosadine a prodrug, which is hydrolyzed intracellularly to the metabolites, 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine (cPrPMEDAP) and 9-(2-phosphonylmethoxyethyl) guanine (PMEG). PMEG is then converted to its active phosphorylated form, which is a chain-terminating inhibitor of the replicative deoxyribonucleic acid (DNA) polymerases.

Approval Year

PubMed

PubMed

TitleDatePubMed
Tanovea® for the treatment of lymphoma in dogs.
2018 Aug
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Administer TANOVEA-CA1 at 1 mg/kg body weight as a 30-minute intravenous infusion, once every three weeks, for up to five doses. Stepwise dose reductions to 0.8 mg/kg and 0.66 mg/kg or dose delays may be used to manage adverse reactions.
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Tue Oct 22 01:38:09 UTC 2019
Edited
by admin
on Tue Oct 22 01:38:09 UTC 2019
Record UNII
3L28LG748I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RABACFOSADINE SUCCINATE
USAN  
USAN  
Official Name English
GS-9219-01
Code English
L-ALANINE, N,N'-(((2-(2-AMINO-6-(CYCLOPROPYLAMINO)-9H-PURIN-9-YL)ETHOXY)METHYL)PHOSPHINYLIDENE)BIS-, DIETHYL ESTER, SUCCINIC ACID SALT (1:1)
Common Name English
VDC-1101-01
Code English
VDC-1101 SUCCINATE
Common Name English
RABACFOSADINE SUCCINATE [USAN]
Common Name English
GS-9219 SUCCINATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C274
Created by admin on Tue Oct 22 01:38:09 UTC 2019 , Edited by admin on Tue Oct 22 01:38:09 UTC 2019
Code System Code Type Description
PUBCHEM
73425536
Created by admin on Tue Oct 22 01:38:09 UTC 2019 , Edited by admin on Tue Oct 22 01:38:09 UTC 2019
PRIMARY
CAS
1431856-99-3
Created by admin on Tue Oct 22 01:38:09 UTC 2019 , Edited by admin on Tue Oct 22 01:38:09 UTC 2019
PRIMARY
NCI_THESAURUS
C152135
Created by admin on Tue Oct 22 01:38:09 UTC 2019 , Edited by admin on Tue Oct 22 01:38:09 UTC 2019
PRIMARY
ChEMBL
CHEMBL1823518
Created by admin on Tue Oct 22 01:38:09 UTC 2019 , Edited by admin on Tue Oct 22 01:38:09 UTC 2019
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY